<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Non-Hodgkin <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (NHL) in children are the second most common <z:mp ids='MP_0002018'>malignant tumors</z:mp> in Kuwait </plain></SENT>
<SENT sid="1" pm="."><plain>Until 1995 the patients (pts) received institutional protocols </plain></SENT>
<SENT sid="2" pm="."><plain>From October 1995 to September 2000 21 children with NHL were treated </plain></SENT>
<SENT sid="3" pm="."><plain>Five children were treated by NHL BFM 90 protocol, 7 pts received NHL BFM 95 scheme, and 9 children underwent therapy abroad or according to different types of protocols </plain></SENT>
<SENT sid="4" pm="."><plain>The results of a retrospective analysis of NHL BFM 95 protocol in Kuwait are reported </plain></SENT>
<SENT sid="5" pm="."><plain>Seven patients diagnosed with NHL--group B: 3 children with Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (B-cell NHL) and group A: 4 children with lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (T-cell NHL)--were treated from October 1995 to September 2000 in the Kuwait <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Control Centre according to NHL BFM 95 protocol </plain></SENT>
<SENT sid="6" pm="."><plain>Group B consisted of 2 girls and 1 boy; median age at diagnosis was 4 years 8 months, 2 pts classified as stage II and 1 pt as stage III </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients were assigned to risk group R2 </plain></SENT>
<SENT sid="8" pm="."><plain>Median follow-up is 2 years 8 months </plain></SENT>
<SENT sid="9" pm="."><plain>Group A included 1 girl and 3 boys; median age at diagnosis was 5 years 8 months, 1 pt classified as stage III and 3 pts as stage IV </plain></SENT>
<SENT sid="10" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients were assigned to IR group </plain></SENT>
<SENT sid="11" pm="."><plain>Median follow-up is 3 years 6 months </plain></SENT>
<SENT sid="12" pm="."><plain>In group B <z:hpo ids='HP_0000001'>all</z:hpo> 3 pts are in 1st CR; in group A 3 pts are in 1st CR and 1 pt having Li-Fraumani syndrome died after the 3rd relapse of disease during therapy </plain></SENT>
<SENT sid="13" pm="."><plain>In both groups there was no toxic <z:hpo ids='HP_0011420'>death</z:hpo>, myelotoxicity WHO grade III-IV, <z:e sem="disease" ids="C0235378,C0348754" disease_type="Disease or Syndrome;Injury or Poisoning" abbrv="">hepatotoxicity</z:e> WHO grade II-III </plain></SENT>
<SENT sid="14" pm="."><plain>Treatment results of NHL BFM 95 study in our small group of patients are very optimistic </plain></SENT>
<SENT sid="15" pm="."><plain>Six patients are in 1st CR and one died due to progression of disease </plain></SENT>
<SENT sid="16" pm="."><plain>Despite the small group of patients, the results suggest that NHL BFM 95 protocol is highly effective and safe with regular supportive care </plain></SENT>
</text></document>